Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 5—May 2007

Resistance to Dihydroartemisinin

On This Page
Article Metrics
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: The title of the letter by Cojean et al. (1) is misleading. The data presented essentially point to an absence of in vitro resistance to dihydroartemisinin (dhART) in the panel of African isolates studied, with 1 of 397 isolates having an elevated 50% inhibitory concentration (IC50) for dhART. The S769N PfATPase6 mutation associated with in vitro resistance to artemether (2) was observed in 1 isolate. This mutant isolate had a low IC50 for dhART, but its IC50 for artemether has not been tested. Since the relationship between in vitro susceptibility to artemether and dhART is still uncertain (3), these data do not disprove the association of a PfATPase6 S769N polymorphism with elevated IC50 for artemether that was observed in isolates from French Guiana (2).

Worth noting is that the association of the S769N PfATPase6 polymorphism with elevated IC50 for artemether was confirmed in an isolate collected in French Guiana in 2005; that isolate had an IC50 for artemether of 127 nmol/L. Molecular typing identified 2 clonal types, 1 with a wild-type PfATPase6 allele and 1 with a S769N single mutant. After 3 weeks of in vitro cultivation without drug, the mutant allele was no longer detected and the IC50 for artemether was 8.2 nmol/L. This finding suggests poor fitness of the mutant allele under standard culture conditions.

The observation of an additional case of in vitro resistance to artemether in French Guiana 3 years after the first cases is of concern. Reinforcement of surveillance is needed as is clarification of the relationship of in vitro susceptibility to artemether and artesunate, the derivatives currently included in artemisinin-based combination therapies (ACTs). Surveillance and clarification would be particularly timely since emerging clinical or parasitologic failures to some ACTs have been reported (4,5).


Eric Legrand*Comments to Author , Beatrice Volney*, Jean-Baptiste Meynard*, Philippe Esterre*, and Odile Mercereau-Puijalon†

Author affiliations: *Institut Pasteur de la Guyane, Cayenne, French Guiana; †Institut Pasteur, Paris, France



  1. Cojean  S, Hubert  V, Le Bras  J, Durand  R. Resistance to dihydroartemisinin. Emerg Infect Dis. 2006;12:17989.PubMed
  2. Jambou  R, Legrand  E, Niang  M, Ing  NK, Lim  P, Volney  B, In vitro artemether resistance of Plasmodium falciparum field isolates and point mutations pf the SERCA-type PfATPase6. Lancet. 2005;366:19603. DOIPubMed
  3. Brockman  A, Price  RN, van Vugt  M, Heppner  DG, Walsh  D, Sookto  P, Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2000;94:53744. DOIPubMed
  4. Grandesso  F, Hagerman  A, Kamara  S, Lam  E, Checchi  F, Balkan  S, Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 in Kailahun, Sierra Leone. Trop Med Int Health. 2006;11:101721. DOIPubMed
  5. Bukirwa  H, Yeka  A, Kamya  MR, Talisuna  A, Banek  K, Bakyaita  N, Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1:e7 . DOIPubMed


Cite This Article

DOI: 10.3201/eid1305.061442

Related Links


Table of Contents – Volume 13, Number 5—May 2007


Please use the form below to submit correspondence to the authors or contact them at the following address:

Address for correspondence: Eric Legrand, Institut Pasteur–CNRCP, 23 Ave Pasteur, PO Box 6010, Cayenne, French Guiana 97306;

Rémy Durand, Hôpital Avicenne, Laboratoire de Parasitologie Mycologie, 125 rue de Stalingrad, 93009 Bobigny Cedex, France

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.


Page created: May 08, 2012
Page updated: May 08, 2012
Page reviewed: May 08, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.